Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema
- PMID: 35833805
- PMCID: PMC9714135
- DOI: 10.1056/NEJMoa2204225
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema
Abstract
Background: In eyes with diabetic macular edema, the relative efficacy of administering aflibercept monotherapy as compared with bevacizumab first with a switch to aflibercept if the eye condition does not improve sufficiently (a form of step therapy) is unclear.
Methods: At 54 clinical sites, we randomly assigned eyes in adults who had diabetic macular edema involving the macular center and a visual-acuity letter score of 24 to 69 (on a scale from 0 to 100, with higher scores indicating better visual acuity; Snellen equivalent, 20/320 to 20/50) to receive either 2.0 mg of intravitreous aflibercept or 1.25 mg of intravitreous bevacizumab. The drug was administered at randomization and thereafter according to the prespecified retreatment protocol. Beginning at 12 weeks, eyes in the bevacizumab-first group were switched to aflibercept therapy if protocol-specified criteria were met. The primary outcome was the mean change in visual acuity over the 2-year trial period. Retinal central subfield thickness and visual acuity at 2 years and safety were also assessed.
Results: A total of 312 eyes (in 270 adults) underwent randomization; 158 eyes were assigned to receive aflibercept monotherapy and 154 to receive bevacizumab first. Over the 2-year period, 70% of the eyes in the bevacizumab-first group were switched to aflibercept therapy. The mean improvement in visual acuity was 15.0 letters in the aflibercept-monotherapy group and 14.0 letters in the bevacizumab-first group (adjusted difference, 0.8 letters; 95% confidence interval, -0.9 to 2.5; P = 0.37). At 2 years, the mean changes in visual acuity and retinal central subfield thickness were similar in the two groups. Serious adverse events (in 52% of the patients in the aflibercept-monotherapy group and in 36% of those in the bevacizumab-first group) and hospitalizations for adverse events (in 48% and 32%, respectively) were more common in the aflibercept-monotherapy group.
Conclusions: In this trial of treatment of moderate vision loss due to diabetic macular edema involving the center of the macula, we found no evidence of a significant difference in visual outcomes over a 2-year period between aflibercept monotherapy and treatment with bevacizumab first with a switch to aflibercept in the case of suboptimal response. (Funded by the National Institutes of Health; Protocol AC ClinicalTrials.gov number, NCT03321513.).
Copyright © 2022 Massachusetts Medical Society.
Figures
Comment in
-
Evidence for Step Therapy in Diabetic Macular Edema.N Engl J Med. 2022 Aug 25;387(8):751-752. doi: 10.1056/NEJMe2208454. Epub 2022 Jul 14. N Engl J Med. 2022. PMID: 35833808 No abstract available.
Similar articles
-
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.N Engl J Med. 2015 Mar 26;372(13):1193-203. doi: 10.1056/NEJMoa1414264. Epub 2015 Feb 18. N Engl J Med. 2015. PMID: 25692915 Free PMC article. Clinical Trial.
-
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.Cochrane Database Syst Rev. 2017 Jun 22;6(6):CD007419. doi: 10.1002/14651858.CD007419.pub5. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2018 Oct 16;10:CD007419. doi: 10.1002/14651858.CD007419.pub6. PMID: 28639415 Free PMC article. Updated. Review.
-
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.Cochrane Database Syst Rev. 2018 Oct 16;10(10):CD007419. doi: 10.1002/14651858.CD007419.pub6. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2023 Jun 27;2023(6):CD007419. doi: 10.1002/14651858.CD007419.pub7. PMID: 30325017 Free PMC article. Updated.
-
Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.JAMA Ophthalmol. 2016 Feb;134(2):127-34. doi: 10.1001/jamaophthalmol.2015.4599. JAMA Ophthalmol. 2016. PMID: 26605836 Free PMC article. Clinical Trial.
-
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.Curr Opin Ophthalmol. 2017 Nov;28(6):636-643. doi: 10.1097/ICU.0000000000000424. Curr Opin Ophthalmol. 2017. PMID: 28837425 Review.
Cited by
-
The Predictors of Early Treatment Effectiveness of Intravitreal Bevacizumab Application in Patients with Diabetic Macular Edema.Diagnostics (Basel). 2024 May 10;14(10):992. doi: 10.3390/diagnostics14100992. Diagnostics (Basel). 2024. PMID: 38786290 Free PMC article.
-
Switching to subtenon triamcinolone acetonide does not jeopardize the functional and anatomic outcomes of dexamethasone implant treated eyes with diabetic macular edema.Graefes Arch Clin Exp Ophthalmol. 2024 Apr 26. doi: 10.1007/s00417-024-06492-z. Online ahead of print. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 38668853
-
Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer.Eur J Nucl Med Mol Imaging. 2024 Apr;51(5):1246-1260. doi: 10.1007/s00259-023-06575-9. Epub 2023 Dec 23. Eur J Nucl Med Mol Imaging. 2024. PMID: 38135849
-
Aflibercept suppresses ovarian hyperstimulation syndrome: an experimental study in rats.Rev Assoc Med Bras (1992). 2023 Oct 27;69(11):e20230789. doi: 10.1590/1806-9282.20230789. eCollection 2023. Rev Assoc Med Bras (1992). 2023. PMID: 37909622 Free PMC article.
-
Trends in Research Payments for Diabetic Macular Edema from 2015 to 2021.Ophthalmol Sci. 2023 Aug 9;4(2):100379. doi: 10.1016/j.xops.2023.100379. eCollection 2024 Mar-Apr. Ophthalmol Sci. 2023. PMID: 37868798 Free PMC article.
References
-
- Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern(R). Ophthalmology. 2020;127(1):P66–P145. - PubMed
-
- Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. - PubMed
-
- Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122(10):2044–2052. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous